^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ecubectedin (PM14)

    i
    Other names: PM14, PM 14
    Associations

    News

    Trials
    Company:
    PharmaMar
    Drug class:
    RNA synthesis inhibitor
    Related drugs:
    Associations

    News

    Trials
    12ms
    Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma. (PubMed, J Exp Clin Cancer Res)
    Collectively, these findings reveal a previously unknown mechanism of action of ecteinascidins that merits further investigation for potential clinical applications in the treatment of MPM, as new first line treatment in monotherapy or in association with immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Tecentriq (atezolizumab) • pemetrexed • Zepzelca (lurbinectedin) • PM54 • ecubectedin (PM14)
    over1year
    PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, PharmaMar | Trial completion date: Feb 2023 --> Aug 2025 | Trial primary completion date: Feb 2023 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    ecubectedin (PM14)
    over2years
    Ecubectedin is a novel transcriptional inhibitor that displays potent antitumor effects in vitro and in vivo (AACR 2023)
    Background - Ecubectedin (PM14) is a novel transcriptional inhibitor related to ecteinascidins family...In mice bearing MDA-MB-231, H526 and 22Rv1 tumors, complete tumor remissions were seen in 1/10 (lasting 103 days), 9/10 (lasting 220 days) and 7/10 (lasting 13 days) ecubectedin-treated animals, respectively.Conclusions - Ecubectedin is a novel transcriptional inhibitor that displays potent antiproliferative activity in different human solid cancer models in vitro and in vivo. The drug is currently in clinical development in Phase II trials.
    Preclinical
    |
    TNFA (Tumor Necrosis Factor-Alpha) • ANXA5 (Annexin A5)
    |
    ecubectedin (PM14)
    over3years
    PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, PharmaMar | Active, not recruiting --> Recruiting
    Enrollment open
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    ecubectedin (PM14)
    4years
    PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Active, not recruiting, PharmaMar | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    ecubectedin (PM14)
    4years
    PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, PharmaMar
    Clinical • New P1 trial
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    ecubectedin (PM14)